Effect of lower-leg trauma and knee arthroscopy on procoagulant phospholipid-dependent activity

Carolina E. Touw MD1,2 | Banne Nemeth MD, PhD1,2 | Willem M. Lijfering MD, PhD1 | Raymond A. van Adrichem MD, PhD1,2 | Line Wilsgård BSc3 | Nadezhda Latysheva PhD3 | Cathrine Ramberg PhD3 | Rob G. H. H. Nelissen MD, PhD2 | John-Bjarne Hansen MD, PhD3,4 | Suzanne C. Cannegieter MD, PhD1,5

1Department of Clinical Epidemiology, Leiden University Medical Center, Leiden, The Netherlands
2Department of Orthopaedics, Leiden University Medical Center, Leiden, The Netherlands
3Thrombosis Research Center (TREC), The Arctic University of Norway, Tromso, Norway
4Division of Internal Medicine, University Hospital of North Norway, Tromsø, Norway
5Department of Internal Medicine, Section of Thrombosis and Haemostasis, Leiden University Medical Center, Leiden, The Netherlands

Correspondence
Carolina E. Touw, Leiden University Medical Center, Department of Clinical Epidemiology, PO Box 9600, 2300 RC Leiden, The Netherlands.
Email: c.e.touw@lumc.nl

Funding information
The authors received no specific funding for this work.

Handling Editor: Dr Neil Zakai

Abstract
Background: Lower-leg injury and knee arthroscopy are both associated with venous thromboembolism (VTE). The mechanism of VTE in both situations is unknown, including the role of procoagulant microparticles. This may provide useful information for individualizing thromboprophylactic treatment in both patient groups.

Objective: We aimed to study the effect of (1) lower-leg trauma and (2) knee arthroscopy on procoagulant phospholipid-dependent (PPL) activity plasma levels.

Methods: POT-(K)CAST trial participants who did not develop VTE were randomly selected for the current study. Plasma was collected shortly after lower-leg trauma or before and after knee arthroscopy. For aim 1, samples of 67 patients with lower-leg injury were compared with control samples (preoperative samples of 74 patients undergoing arthroscopy). Linear regression was used to obtain mean ratios (natural logarithm retransformed data), adjusted for age, sex, body mass index, infections, and comorbidities. For aim 2, pre- and postoperative samples of 49 patients undergoing arthroscopy were compared using paired t tests. PPL activity was measured using modified activated factor X–dependent PPL clotting assay.

Results: For aim 1, PPL activity levels were almost threefold higher in patients with lower-leg injury compared with controls, that is, mean ratio, 2.82 (95% confidence interval [CI], 1.98–4.03). For aim 2, postoperative PPL activity levels did not change significantly, that is, mean change, −0.72 mU/mL (95% CI, −2.03 to 0.59).

Conclusion: Lower-leg trauma was associated with increased plasma levels of PPL activity, in contrast to knee arthroscopy. Lower-leg trauma triggers the release of procoagulant microparticles.

KEYWORDS
arthroscopy, blood coagulation, cell-derived microparticles, knee injuries, leg injuries, venous thromboembolism
Venous thromboembolism (VTE) is associated with serious mortality and chronic morbidity. Patients with lower-leg injury or who undergo knee arthroscopic surgery have an increased risk of VTE in the following months. There is controversy on the optimal form of thromboprophylaxis in these patient groups: a “one-size-fits-all” approach of low-molecular-weight-heparin (LMWH) treatment does not sufficiently prevent VTE, as was concluded in two randomized controlled trials, the POT-(K)AST trials. These trials demonstrated that the occurrence of VTE in the first 3 months following lower-leg cast application or knee arthroscopy was similar for patients treated with LMWH compared with patients who did not receive any thromboprophylaxis. For lower-leg cast immobilization (POT-CAST; Prevention of Thrombosis Following Cast Immobilization), 1.4% of patients treated with LMWH and 1.8% of patients in the control group developed VTE. For knee arthroscopy (POT-KAST; Prevention of Thrombosis Following Knee Arthroscopy), these risks were 0.7% and 0.4%, respectively.

A possible approach to improve thrombosis prevention may be to identify new prevention targets. For this, knowledge of the mechanism of how lower-leg trauma and knee arthroscopy trigger thrombus formation could be helpful. However, the exact mechanism is as yet unclear, including the role of extracellular vesicles (EVs). Over the past years, EVs in plasma, also known as “microparticles,” have been shown to play an important role in clot formation in general. Moreover, their presence in plasma is found to be associated with VTE. EVs are bilayer phospholipid membrane vesicles in plasma, derived from cell activation, which can be triggered by inflammation and apoptosis. The surface of EVs is enriched with negatively charged phospholipids, phosphatidylserine (PS) in particular, due to translocation from the inner layer of the membrane during the formation process. EVs are procoagulant, as PS facilitates the assembly of positively charged coagulation factors (including prothrombin and factors VII, IX, and X) and enhances intrinsic tenase complex activity. This phenomenon is referred to as procoagulant phospholipid-dependent (PPL) activity.

To elucidate whether lower-leg trauma and knee arthroscopy trigger the release of procoagulant EVs in plasma, we aimed to establish the effects of (1) lower-leg trauma and (2) knee arthroscopy on PPL activity in plasma. For this purpose, we used data from the POT-(K)CAST trials.

2.1 Study population

Data of individuals with lower-leg injury and individuals scheduled for knee arthroscopy who participated in the POT-CAST and POT-KAST trials, respectively, were used. As described previously, the aim of these trials was to study the effectiveness of LMWH as prophylactic treatment in these populations by assessing the occurrence of symptomatic VTE in the first 3 months. In both trials, patients were randomly assigned to either LMWH in prophylactic dose or no prophylaxis. Both trials took place between March 2012 and January 2016. POT-CAST participants were enrolled upon presentation at the emergency department with a lower-leg injury, while POT-KAST participants were included when they were scheduled for elective knee arthroscopy. Patients who were aged ≥18 years and who did not meet following exclusion criteria were eligible for inclusion: history of VTE, current use of anticoagulant therapy (except antiplatelet medication), contraindications for LMWH, pregnancy, mental or physical disability to fulfill study requirements, or insufficient knowledge of the Dutch language.

All participants completed a questionnaire on putative thrombotic risk factors. Specific details about lower-leg injuries and knee arthroscopic procedures were derived from medical records. A blood sample was provided by POT-CAST (leg injury) participants shortly after trauma, at all times before any surgical procedure took place. POT-KAST participants provided two blood samples: one preoperative sample (drawn within 4 hours before surgery) and one postoperative sample (drawn within 4 hours after surgery). All individuals who were randomized to prophylactic LMWH received the first dose of LMWH after blood sampling. In this way, measurements of PPL activity in plasma were not affected by LMWH. The Medical Ethics Committee of Leiden University Medical Center approved both trials, and all patients who participated in the trials provided informed consent.
between lower-leg injury or knee arthroscopy and PPL activity levels was avoided by including only those individuals who did not develop VTE during trial follow-up.

For the first research question, that is, whether lower-leg trauma is associated with increased levels of PPL activity, samples of 67 randomly chosen individuals with lower-leg trauma (POT-CAST trial) were used for measurements, further referred to as “subjects with lower-leg injury.” As control samples, we used the preoperative blood samples (ie, at baseline) of 74 randomly selected patients undergoing knee arthroscopy, further referred to as “subjects without lower-leg injury.” We chose to use these samples as control samples because they were processed, stored, and analyzed in the same way. Furthermore, the most prevalent indications for arthroscopy for these subjects were either unexplained complaints (diagnostic indication) or persisting residual complaints after minor knee trauma in the distant past (for which physical therapy appeared inadequate). Hence, at the time of blood draw, no acute trauma was present that could have affected PPL activity. For the second research question, that is, whether knee arthroscopy was associated with increased PPL activity levels, pre- and postoperative blood samples were compared for 49 of the 74 randomly selected patients undergoing knee arthroscopy, further referred to as “knee arthroscopy patients.” Of the remaining 25 patients, no postoperative blood sample was available; therefore, they were excluded for these analyses.

2.3 Blood collection and laboratory measurements

Blood was collected from all participants through vena puncture in the cubital vein and drawn into vacuum citrate tubes (0.105 M, 3.2%). These tubes were centrifuged during 10 minutes at 2500 g at 18°C. The resulting plasma was aliquoted and stored at −80°C within 4 hours after vena puncture.

For current PPL measurements, the citrated platelet-poor plasma (PPP) samples were thawed for the first time. Modified activated factor X (factor Xa)-dependent PPL clotting assay was used, as described previously. In short, PPP samples were centrifuged at a speed of 13 500 g for 2 minutes to generate platelet-free plasma (PPF). Test plasma was mixed in equal amounts of 25 μL with 25 μL PPL-depleted plasma (phospholipid-depleted plasma [PPLDP]), incubated for 2 minutes before the reaction was initiated by the addition of 100 μL prewarmed factor Xa reagent (0.1 U/mL bovine factor Xa in 15 mM calcium chloride, 100 mM sodium chloride and 20 mM HEPES buffer, pH 7.0). A commercially available standardized reagent containing 0.1% of rabbit brain cephalin in a buffered solution was used as calibrator (UPTT; Bio/Data Corporation, Horsham, PA, USA). Clotting tests were carried out in duplicate on a StarT4 instrument (Diagnostica Stago, Parsippany, NJ, USA). PPL levels were measured in seconds of clotting time and converted to mU/mL, by the use of the UPTT calibrator. PPLDP was prepared.
from pooled citrated PFP (n = 18) centrifuged at 100 000 g for 60 minutes at 16°C (Beckman Optima LE-80K Ultracentrifuge, rotor SW40Ti; Beckman Coulter, Indianapolis, IN, USA), stored in aliquots of 0.5 mL and frozen until further use. The PPL assay displayed a low coefficient of variation of ≤4% and variation between runs was adjusted for by an internal standard (pooled PFP).

2.4 | Statistical analysis

2.4.1 | Aim 1: Effect of lower-leg injury on PPL activity

Subjects with and without lower-leg injury were compared in terms of plasma levels of PPL activity expressed in milliunits per milliliter, using descriptive statistics and linear regression models. Data had to be transformed using natural logarithms (ln), since PPL was not normally distributed. To obtain geometric means, the ln of all PPL values was computed, after which the mean of ln-PPL was calculated and re-transformed by calculating $e^{(mean \ ln-PPL)}$, resulting in the geometric mean. In linear regression models, ln-PPL was included as the dependent variable. Since the outcome estimate of linear regression is mean difference, for ln-transformed variables, this involves $ln(b) - ln(a)$, which equals $ln(b/a)$. Therefore, by retransforming the outcome of linear regression, that is, $e^{(ln(b/a))}$, a mean ratio (ie, b/a) is obtained. The geometric means and mean ratios were obtained with their 95% confidence intervals (95% CIs). The mean ratios were adjusted for age, sex, body mass index (BMI), comorbidities and infections (in the past 2 months). BMI was included as a continuous variable in the model. Comorbidities included chronic obstructive pulmonary disease (COPD), liver disease, kidney disease, rheumatoid arthritis, multiple sclerosis, heart failure, hemorrhagic stroke, and arterial thrombosis.

To observe whether timing of blood sampling affected our results, we plotted PPL activity levels against the time between lower-leg trauma and blood sampling in a scatterplot, in which the slope of the regression line was calculated. Furthermore, we performed a sensitivity analysis, calculating the crude and adjusted mean ratio restricted to subjects in whom blood was sampled on day 0 or day 1 after trauma occurred. In addition, PPL activity levels were stratified for types of injury ordered by magnitude.

2.4.2 | Aim 2: Effect of knee arthroscopy on PPL activity

The comparison of pre- and postoperative PPL activity levels in patients undergoing arthroscopy led to paired differences. Since these differences were normally distributed, paired mean changes were calculated along with their 95% CIs.

All analyses were performed using Stata 16.0 (StataCorp, College Station, TX, USA; http://www.stata.com). Figures were composed using Prism version 9.0.1 (GraphPad Software, San Diego, CA, USA; http://www.graphpad.com).

2.5 | Sample size considerations

Before this study, we performed sample size calculations in which we aimed to achieve a power of 90% and a level of significance of 0.05 (two-sided). Based on the results of a pilot study that we performed before the current study, we anticipated a mean difference or change of 3 mU/mL with a standard deviation of 4 mU/mL, resulting in a minimal sample size of 76 individuals in total (ie, 38 subjects with and 38 subjects without lower-leg injury) for aim 1 and 22 individuals (ie, pairs) for aim 2.

3 | RESULTS

3.1 | Aim 1: Effect of lower-leg injury on PPL activity

Subjects with and without lower-leg injury were comparable in terms of general patient characteristics (Table 1). Both patient groups involved slightly more men (56.7% and 54.1%, respectively) and had a similar median age (54.9 and 51.0 years, respectively), and the majority had BMI >25 (68.2% and 69.9%, respectively). Most lower-leg injuries concerned an ankle fracture (32.8%) or foot fracture (62.7%). Of all injuries, 13.4% were treated surgically. In a majority of the subjects, blood was sampled within 24 hours after trauma occurred (69.7%).

Plasma levels of PPL activity in both patient groups were right-skewed (Figure 2). Subjects with lower-leg injury had a geometric mean PPL of 4.63 mU/mL (95% CI, 3.81–5.62), while this was 1.62 mU/mL (95% CI, 1.23–2.14) in subjects without lower-leg injury, resulting in an almost three times higher mean plasma level of PPL activity (mean ratio, 2.94; 95% CI, 2.04–4.24). Adjusting for age, sex, BMI, comorbidities, and infections in the past 2 months hardly affected this result (mean ratio, 2.82; 95% CI, 1.98–4.03; Table 3). Figure S1 shows that mean levels of PPL activity remained the same over time, although there were more extreme values (both increased and decreased) observed on day 0 or 1 after lower-leg trauma occurrence as compared with a later blood draw. In line with this observation, the sensitivity analysis, that is, restricted to subjects with blood sampling on day 0 or 1 after trauma (57 subjects in total, which involves 85% of all subjects with lower-leg injury), showed that mean ratios were only slightly higher: a crude ratio of 2.94 (95% CI, 2.04–4.24) and an adjusted ratio of 3.05 (95% CI, 2.10–4.5). Stratified analyses showed that PPL activity increased in all different subtypes of lower-leg injury compared to subjects without, although the magnitude of lower-leg injury did not seem to correlate with PPL activity (Figure 3).

3.2 | Aim 2: Effect of knee arthroscopy on PPL activity

Postoperative plasma levels of PPL activity were measured in 49 patients undergoing knee arthroscopy. These patients were mostly men (57.1%), and the median age was 51.0 years. The majority were
### Table 1: General characteristics of subjects with and without lower-leg injury

|                         | Subjects with lower-leg injury (N = 67) | Subjects without lower-leg injury (N = 74) |
|-------------------------|----------------------------------------|------------------------------------------|
| **Sex**                 |                                        |                                          |
| Male, n (%)             | 38 (56.7)                              | 40 (54.1)                                |
| **Age**                 |                                        |                                          |
| Median, y (IQR)         | 54.9 (46.1-60.6)                       | 51.0 (44.0-57.3)                        |
| **BMI**                 |                                        |                                          |
| <20 kg m⁻², n (%)       | 0 (0.0)                                | 1 (1.4)                                  |
| 20–25 kg m⁻², n (%)     | 20 (30.3)                              | 21 (28.8)                                |
| 25–30 kg m⁻², n (%)     | 30 (45.5)                              | 33 (45.2)                                |
| >30 kg m⁻², n (%)       | 16 (24.2)                              | 18 (24.7)                                |
| **At least one comorbidity** |                                        |                                          |
| Yes, n (%)              | 12 (18.2)                              | 6 (8.2)                                  |
| **Infection in past 2 months** |                                        |                                          |
| Yes, n (%)              | 8 (12.5)                               | 7 (9.6)                                  |
| **Smoking**             |                                        |                                          |
| Yes: currently, n (%)   | 18 (27.7)                              | 19 (26.0)                                |
| Yes: formerly, n (%)    | 26 (40.0)                              | 20 (27.4)                                |
| **Current use of oral contraceptives** |                                        |                                          |
| Yes, n (%)              | 1 (3.7)                                | 3 (9.1)                                  |
| **Malignancy in past year** |                                        |                                          |
| Yes, n (%)              | 1 (1.5)                                | 0 (0.0)                                  |
| **ABO blood type**      |                                        |                                          |
| Homozygote O, n (%)     | 26 (41.9)                              | 33 (45.2)                                |
| Heterozygote O, n (%)   | 31 (50.0)                              | 33 (45.2)                                |
| Homozygote non-O, n (%) | 5 (8.1)                                | 7 (9.6)                                  |
| **Factor V Leiden**     |                                        |                                          |
| Yes: heterozygote, n (%)| 2 (3.2)                                | 3 (4.1)                                  |
| No, n (%)               | 60 (96.8)                              | 71 (95.9)                                |
| **Administration of prophylactic LMWH after blood sampling** |                                        |                                          |
| Yes, n (%)              | 31 (46.3)                              | 38 (51.4)                                |
| **Type of lower-leg injury** |                                        |                                          |
| Achilles tendon rupture, n (%) | 2 (3.0)                              | NA                                       |
| Ankle distortion, n (%) | 1 (1.5)                                | NA                                       |
| Ankle fracture, n (%)   | 22 (32.8)                              | NA                                       |
| Foot fracture, n (%)    | 42 (62.7)                              | NA                                       |
| **Surgical treatment of injury** |                                        |                                          |
| Yes, n (%)              | 9 (13.4)                               | NA                                       |
| **Time between trauma and blood sampling** |                                        |                                          |
| Within 24 h, n (%)      | 46 (69.7)                              | NA                                       |
| Within 7 days, n (%)    | 17 (25.8)                              | NA                                       |
| After 7 days, n (%)     | 3 (4.5)                                | NA                                       |

BMI, body mass index; IQR, interquartile range (25th–75th percentile); LMWH, low-molecular-weight heparin; NA, not applicable.

*aIncluding hormonal therapy.

Meniscectomies (69.4%), and in 98% a tourniquet was used. Most patients underwent surgery under general anaesthesia (69.4%; Table 2). The preoperative geometric mean of PPL activity was 1.35 mU/mL (95% CI, 1.00-1.82), and postoperatively this was 1.05 mU/mL (95% CI, 0.78-1.40). The mean change was −0.72 mU/mL (95% CI, −2.03 to 0.59; Table 3).
We found lower-leg injury to be associated with almost threefold increased plasma levels of PPL activity, indicating that lower-leg trauma triggers the release of PS-bearing microparticles. In contrast, the “trauma” of knee arthroscopy (generally in combination with tourniquet use) did not affect PPL activity levels.

A positive association between lower-leg injury and release of procoagulant EVs has not been studied before. In contrast, the effect of major injury on EVs has been reported earlier,\textsuperscript{19-21} although the results of these studies cannot be compared easily with our results. Major trauma has a greater impact on the coagulation system than lower-leg trauma because of factors such as high-volume blood loss, blood transfusion, consumption of clotting factors, and multiple injuries (and its associated tissue damage).\textsuperscript{19,20} Partly based on these studies, we can speculate on the mechanism by which lower-leg trauma triggers EV release: Vessel wall damage induced by trauma activates endothelial cells and platelets, which are both main providers of EVs (especially platelets for 70%–90%). As a result, PS is translocated to the cell’s surface, which initiates the formation of EVs.\textsuperscript{11,22-24} EVs are procoagulant due to the presence of PS on their surface, expressed as PPL activity, and tissue factor (TF). PS and TF stimulate thrombus formation through thrombin generation, by promoting positively
charged coagulation factors and initiating (the extrinsic pathway
of) the coagulation cascade, respectively. It depends on the
cell origin and the mechanism of cell activation whether PS or TF is
present on EVs. For that matter, endothelial cells release negligible
amounts of TF+EVs upon apoptosis. To obtain more insight into this process, two additional analyses
regarding the association between lower-leg trauma and PPL activ-
ity levels were performed. First, since it can be hypothesized that a
greater amount of tissue damage (ie, severe injuries) invokes more
release of PS+EVs, we stratified the analyses for magnitude of lower-
l w

| TABLE 2 Aim 2: General characteristics of patients undergoing knee arthroscopy | Patients undergoing knee arthroscopy (N = 49) |
|---|---|
| Sex | Male, n (%) 28 (57.1) |
| Age, y | Median (IQR) 51.0 (42.5-57.0) |
| BMI | <20 kg m⁻², n (%) 1 (2.1) |
| | 20-25 kg m⁻², n (%) 15 (31.3) |
| | 25-30 kg m⁻², n (%) 19 (39.6) |
| | >30 kg m⁻², n (%) 13 (27.1) |
| At least one comorbidity | Yes, n (%) 4 (8.3) |
| Infection in past 2 months | Yes, n (%) 4 (8.3) |
| Smoking | Yes: currently, n (%) 14 (29.2) |
| | Yes: formerly, n (%) 16 (33.3) |
| Current use of oral contraceptives | Yes, n (%) of women 1 (5.0) |
| Malignancy in past year | Yes, n (%) 0 (0.0) |
| ABO blood type | Homozygote O, n (%) 22 (44.9) |
| | Heterozygote O, n (%) 21 (42.9) |
| | Homozygote non-O, n (%) 6 (12.2) |
| Factor V Leiden | Yes: heterozygote, n (%) 2 (4.1) |
| | No, n (%) 47 (95.9) |
| Administration of prophylactic LMWH after blood sampling | Yes, n (%) 27 (55.1) |
| Type of procedure | Meniscectomy, n (%) 34 (69.4) |
| | Diagnostic arthroscopy, n (%) 2 (4.1) |
| | Removal of loose bodies, n (%) 2 (4.1) |
| | Other, n (%) 2 (4.1) |
| | Multiple procedures, n (%) 9 (18.4) |
| ASA classification | ASA I, n (%) 26 (57.8) |
| | ASA II, n (%) 18 (40.0) |
| | ASA III, n (%) 1 (2.2) |
| Type of anesthesia | General, n (%) 34 (69.4) |
| | Spinal, n (%) 15 (30.6) |
| Use of thigh tourniquet | Yes, n (%) 48 (98.0) |

(Continues)
within 4 hours, was too early to measure an effect. However, after knee replacement, the peak of EVs was measured at 2.5 hours after the surgery, and was still elevated after 8 hours. That is, the postoperative time frame to measure PPL activity in our study seems to be appropriate. Furthermore, it is possible that administration of intravenous saline affected postoperative PPL activity levels. However, patients received at most 0.5 L of saline during surgery. Also, considering that this would be excreted by the kidneys in a short time period, it is not likely this could have resulted in a strong dilution of PPL plasma levels.

A strength of our study was that we used modified factor Xa-dependent clotting assay. This is a functional assay that measures the activity, that is, procoagulant contribution, of EVs, which is unknown when only the amount of EVs is measured. Since presence of PS on EVs induces a high procoagulant ability, and given that our measurement approach strongly correlates with the amount of PS+EVs present in plasma, our findings give an adequate indication of the association between lower-leg trauma or knee arthroscopy and the expression of procoagulant EVs in plasma. Moreover, this clot-based assay has been studied in healthy volunteers and characterized as a convenient and fast measuring technique with a high sensitivity, suitable for use in clinical practice. Other strengths of our study were that all samples were collected before LMWH was administered, so our results were not affected by LMWH. Finally, for knee arthroscopy, patients served as their own control group and for subjects with lower-leg injury, a similar control group was used with application of the same methods.

Some limitations of our study should also be mentioned. First, PPL was measured >6 years after blood collection. It is possible that sample storage in the freezer at −80°C affected plasma levels of EVs and thereby those of PPL activity. Such a storage effect would have affected all samples equally, but a small effect of such nondifferential misclassification on the comparison cannot be excluded. Second, the modified factor Xa-dependent clotting assay only measures the amount of PS+EVs and is insensitive to TF+EVs. While TF contributes to the procoagulant state of EVs, the actual procoagulant state of EVs could be even higher than we have measured. Finally, no information was available on the race of POT-(K)CAST participants. Although there is limited knowledge about the effect of race on plasma levels of (procoagulant) EVs, a study comparing African and White Americans did not show any differences in circulating EVs, suggesting that any effect of race in our study was minimal.

Information about the effect of lower-leg injury and knee arthroscopy on the release of procoagulant EVs is useful in order to understand the mechanism of VTE following both events, which is as yet unclear. Understanding the mechanism on its turn could be helpful to improve currently applied thromboprophylaxis strategies by the identification of new and more effective prevention targets for VTE. This is necessary, given that the VTE risk remains high under a prophylactic dose of LMWH (especially in patients with a lower-leg cast). Additional research is necessary, where it should be established whether PPL activity levels are elevated on the long term (for which longitudinal data are necessary), and if and for how long these elevations are associated with increased VTE risk.

In conclusion, lower-leg trauma was associated with increased PPL activity levels in plasma, while after knee arthroscopy no increase was demonstrated. Therefore, it can be assumed that release of PS+EVs is part of the mechanism of hypercoagulability in patients with lower-leg injury and that the mechanism of thrombus formation differs, at least to some extent, between lower-leg trauma and knee arthroscopy.

**AUTHOR CONTRIBUTIONS**
SCC designed the current study and set up the original trials with RGHHN. In both trials, samples and data were collected by BN and...
RAA. LW, NL, CR, and JBH set up and performed PPL activity measurements. CET performed data analyses and wrote the initial draft of the manuscript. CET, BN, WML, and SCC interpreted the results and wrote the manuscript. All authors read the manuscript and contributed to the final version.

ACKNOWLEDGMENTS
The authors would like to thank Ingeborg de Jonge and Petra Noordijk for the helpful support in samples collection and preparation. We also acknowledge the Thrombosis Research Center at the Arctic University of Norway, where the measurements were performed.

RELATIONSHIP DISCLOSURE
All authors declare no competing financial or other interests.

ORCID
Carolina E. Touw https://orcid.org/0000-0002-7993-5209
Banne Nemeth https://orcid.org/0000-0002-1214-5923
Willem M. Lijfering https://orcid.org/0000-0002-4638-4623
John-Bjarne Hansen https://orcid.org/0000-0003-4854-3162
Suzanne C. Cannegieter https://orcid.org/0000-0003-4707-2303

REFERENCES
1. Alotaibi GS, Wu C, Senthilselvan A, McMurry MS. Secular trends in incidence and mortality of acute venous thromboembolism: the AB-VTE population-based study. Am J Med. 2016;129(8):879.e19-879.e25.
2. Piazza G, Goldhaber SZ. Chronic thromboembolic pulmonary hypertension. N Engl J Med. 2011;364:351-360.
3. Baldwin MJ, Moore HM, Rudarakantha N, Gohel M, Davies AH. Post-thrombotic syndrome: a clinical review. J Thromb Haemost. 2013;11:795-805.
4. Maletis GB, Inacio MC, Reynolds S, Funahashi TT. Incidence of symptomatic venous thromboembolism after elective knee arthroscopy. J Bone Joint Surg. 2012;94:714-720.
5. Nemeth B, Cannegieter SC. Venous thrombosis following lower-limb cast immobilization and knee arthroscopy: from a population-based approach to individualized therapy. Thromb Res. 2019;174:62-75.
6. Selby R, Geerts WH, Kreder HJ, Crowther MA, Kaus L, Sealey F. Symptomatic venous thromboembolism uncommon without thrombophilia after isolated lower-limb fracture: the knee-to-ankle fracture (KAF) cohort study. J Bone Joint Surg. 2014;96:e83.
7. van Adrichem RA, Nemeth B, Algra A, et al. Thromboprophylaxis after knee arthroscopy and lower-limb casting. N Engl J Med. 2017;376:515-525.
8. Owens AP 3rd, Mackman N. Microparticles in hemostasis and thrombosis. Circ Res. 2011;108:1284-1297.
9. Bucciarelli P, Martinelli I, Artoni A, et al. Circulating microparticles and risk of venous thromboembolism. Thromb Res. 2012;129:591-597.
10. Enjeti AK, Lincz LF, Seldon M. Microparticles in health and disease. Semin Thromb Hemost. 2008;34:683-691.
11. Morel O, Jesel L, Freyssinet JM, Toti F. Cellular mechanisms underlying the formation of circulating microparticles. Arterioscler Thromb Vasc Biol. 2011;31:15-26.
12. Ayers L, Nieuwland R, Kohler M, Kraenkel N, Ferry B, Leeson P. Dynamic microvesicle release and clearance within the cardiovascular system: triggers and mechanisms. Clin Sci. 1979;2015(129):915-931.
13. van der Pol E, Boing AN, Harrison P, Sturk A, Nieuwland R. Classification, functions, and clinical relevance of extracellular vesicles. Pharmocol Rev. 2012;64:676-705.
14. Ruf W, Rehemtulla A, Morrissey JH, Edgington TS. Phospholipid-independent and-dependent interactions required for tissue factor receptor and cofactor function. J Biol Chem. 1991;266:2158-2166.
15. Freyssinet JM, Toti F. Formation of procoagulant microparticles and properties. Thromb Res. 2010;125(suppl 1):S46-S48.
16. Heemskerk JW, Bevers EM, Lindhout T. Platelet activation and blood coagulation. Thromb Haemost. 2002;88:186-193.
17. Zwaal RF, Schroit AJ. Pathophysiologic implications of membrane phospholipid asymmetry in blood cells. Blood. 1997;89:1121-1132.
18. Ramberg C, Jamaly S, Latysheva N, et al. A modified clot-based assay to measure negatively charged procoagulant phospholipids. Sci Rep. 2021;11:9341.
19. Park MS, Owen BA, Ballinger BA, et al. Quantification of hypercoagulable state after blunt trauma: microparticle and thrombin generation are increased relative to injury severity, while standard markers are not. Surgery. 2012;151:831-836.
20. Dyer MR, Alexander W, Hassoune A, et al. Platelet-derived extracellular vesicles released after trauma promote hemostasis and contribute to DVT in mice. J Thromb Haemost. 2019;17:1733-1745.
21. Curry N, Raju A, Beavis J, Stanworth S, Harrison P. Levels of procoagulant microvesicles are elevated after traumatic injury and platelet microvesicles are negatively correlated with mortality. J Extracell Vesicles. 2014;3:25625.
22. Aartonen M, Grönholm M, Siljander PR. Platelet-derived microvesicles: multitalented participants in intercellular communication. Semin Thromb Hemost. 2012;38:102-113.
23. Bal L, Edery S, Di Angelantonio E, et al. Circulating procoagulant microparticles in acute pulmonary embolism: a case-control study. Int J Cardiol. 2010;145:321-322.
24. Brisson AR, Tan S, Linares R, Gounou C, Arraud N. Extracellular vesicles from activated platelets: a semiquantitative cryo-electron microscopy and immuno-gold labeling study. Platelets. 2017;28:263-271.
25. Grover SP, Mackman N. Tissue factor: an essential mediator of hemostasis and trigger of thrombosis. Arterioscler Thromb Vasc Biol. 2018;38:709-725.
26. Mooberry MJ, Key NS. Microparticle analysis in disorders of hemostasis and thrombosis. Cytometry A. 2016;89:111-122.
27. Lechner D, Weltermann A. Circulating tissue factor-exposing microparticles. Thromb Res. 2008;122(suppl 1):S47-S54.
28. Rank A, Nieuwland R, Crispin A, et al. Clearance of platelet microvesicles in vivo. Platelets. 2011;22:111-116.
29. Bovill EG, van der Vliet A. Venous valvar stasis-associated hypoxia and thrombosis: what is the link? Annu Rev Physiol. 2011;73:527-545.
30. Kageyama K, Nakajima Y, Shibasaki M, Hashimoto S, Mizobe T. Increased platelet, leukocyte, and endothelial cell activity are associated with increased coagulability in patients after total knee arthroplasty. J Thromb Haemost. 2007;5:738-745.
31. Connor DE, Exner T, Ma DD, Joseph JE. Detection of the procoagulant activity of microparticle-associated phosphatidylserine using XACT. Blood Coagul Fibrinol. 2009;20:558-564.
32. Ayers L, Harrison P, Kohler M, Ferry B. Procoagulant and platelet-derived microvesicle absolute counts determined by flow cytometry correlates with a measurement of their functional capacity. J Extracell Vesicles. 2014;3(1):25348.

TWITTER
Banne Nemeth @bannenemeth
Suzanne C. Cannegieter @s_cannegieter
33. Ho P, Ng C, Rigano J, et al. Significant age, race and gender differences in global coagulation assays parameters in the normal population. Thromb Res. 2017;154:80-83.

34. van Adrichem RA, Debeij J, Nelissen RG, Schipper IB, Rosendaal FR, Cannegieter SC. Below-knee cast immobilization and the risk of venous thrombosis: results from a large population-based case-control study. J Thromb Haemost. 2014;12:1461-1469.

35. van Adrichem RA, Nelissen RG, Schipper IB, Rosendaal FR, Cannegieter SC. Risk of venous thrombosis after arthroscopy of the knee: results from a large population-based case-control study. J Thromb Haemost. 2015;13:1441-1448.

36. Huang HF, Tian JL, Sun L, et al. The effect of anticoagulants on venous thrombosis prevention after knee arthroscopy: a systematic review. Int Orthop. 2019;43:2303-2308.

**SUPPORTING INFORMATION**

Additional supporting information may be found in the online version of the article at the publisher’s website.

**How to cite this article:** Touw CE, Nemeth B, Lijfering WM, et al. Effect of lower-leg trauma and knee arthroscopy on procoagulant phospholipid-dependent activity. Res Pract Thromb Haemost. 2022;6:e12729. doi:10.1002/rth2.12729